Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03835533
Title Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER)
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Parker Institute for Cancer Immunotherapy

prostate cancer


CDX-301 + INO-5151 + Nivolumab

CDX-301 + Nivolumab + Poly ICLC

Nivolumab + NKTR-214

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.